Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug

[Reuters] – Slowing sales of Biogen Inc’s key oral multiple sclerosis (MS) drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer’s drug sent the company’s stock down as . . . → Read More: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Similar Articles: Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen says Tecfidera sales slow, delays data readout on Alzheimer’s drug